Mosaic ImmunoEngineering annual r&d spending
2020
2021
2022
2023
2024
2025
Mosaic ImmunoEngineering R&D Spending Growth & History (CPMV)
Mosaic ImmunoEngineering's r&d spending was $63,981 for fiscal 2025.
View full Mosaic ImmunoEngineering company overviewMosaic ImmunoEngineering annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $63,981 | −$119,886 | −65.20% |
| 2024 | 2024-12-31 | $183,867 | −$251,582 | −57.78% |
| 2023 | 2023-12-31 | $435,449 | −$613,008 | −58.47% |
| 2022 | 2022-12-31 | $1.0M | −$407,662 | −28.00% |
| 2021 | 2021-12-31 | $1.5M | $1.1M | +324.86% |
| 2020 · Dec 31 | 2020-12-31 | $342,727 | — | — |
Mosaic ImmunoEngineering quarterly r&d spending
Q1.11
Q2.11
Q1.12
Q2.12
Q2.20
Q1.21
Q1.21
Q2.21
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $15,608 | −$398 | −2.49% |
| Q1 2026 | 2026-03-31 | $15,880 | $77 | +0.49% |
| Q4 2025 | 2025-12-31 | $16,133 | −$117 | −0.72% |
| Q3 2025 | 2025-09-30 | $16,039 | −$23,560 | −59.50% |
| Q2 2025 | 2025-06-30 | $16,006 | −$44,701 | −73.63% |
| Q1 2025 | 2025-03-31 | $15,803 | −$51,508 | −76.52% |
| Q4 2024 | 2024-12-31 | $16,250 | −$33,739 | −67.49% |
| Q3 2024 | 2024-09-30 | $39,599 | −$45,328 | −53.37% |
| Q2 2024 | 2024-06-30 | $60,707 | −$61,931 | −50.50% |
| Q1 2024 | 2024-03-31 | $67,311 | −$110,584 | −62.16% |
| Q4 2023 | 2023-12-31 | $49,989 | −$157,033 | −75.85% |
| Q3 2023 | 2023-09-30 | $84,927 | −$126,155 | −59.77% |
| Q2 2023 | 2023-06-30 | $122,638 | −$180,056 | −59.48% |
| Q1 2023 | 2023-03-31 | $177,895 | −$149,764 | −45.71% |
| Q4 2022 | 2022-12-31 | $207,022 | −$186,256 | −47.36% |
| Q3 2022 | 2022-09-30 | $211,082 | −$228,844 | −52.02% |
| Q2 2022 | 2022-06-30 | $302,694 | −$74,073 | −19.66% |
| Q1 2022 | 2022-03-31 | $327,659 | $81,511 | +33.11% |
| Q4 2021 | 2021-12-31 | $393,278 | — | — |
| Q3 2021 | 2021-09-30 | $439,926 | $219,843 | +99.89% |
| Q2 2021 · Jun 30 | 2021-06-30 | $376,767 | $376,767 | — |
| Q1 2021 · Mar 31 | 2021-03-31 | $246,148 | — | — |
| Q2 2021 · Nov 30 | 2020-11-30 | $252,147 | — | — |
| Q1 2021 · Sep 30 | 2020-09-30 | $220,083 | — | — |
| Q1 2021 · Aug 31 | 2020-08-31 | $83,507 | — | — |
| Q2 2020 · Jun 30 | 2020-06-30 | $0 | — | — |
| Q2 2012 | 2011-11-30 | $150,757 | −$6,788 | −4.31% |
| Q1 2012 | 2011-08-31 | $170,195 | −$60,289 | −26.16% |
| Q2 2011 | 2010-11-30 | $157,545 | — | — |
| Q1 2011 | 2010-08-31 | $230,484 | — | — |
Mosaic ImmunoEngineering r&d spending trends
Over the last five fiscal years, Mosaic ImmunoEngineering's r&d spending decreased from $342,727 to $63,981, a change of −$278,746. The latest reported quarter, Q2 2026, shows $15,608.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Mosaic ImmunoEngineering source filings ↗